摘要
目的：探讨非霍奇金淋巴瘤（NHL）患者血清β2-微球蛋白（β2-MG）和CA125检测的临床意义。方法检测76例NHL患者及32例体检健康者的血清β2-MG和CA125水平，分析β2-MG和CA125与疾病临床进展及预后的关系。结果 NHL患者血清β2-MG和CA125水平高于健康体检者（P〈0.05）；β2-MG和CA125水平与患者年龄和性别均无相关性（P〉0.05）；侵袭性和高侵袭性淋巴瘤患者的β2-MG和CA125水平比惰性淋巴瘤患者高（P〈0.05）；Ⅲ～Ⅳ期比Ⅰ～Ⅱ期患者的β2-MG和CA125水平高（P〈0.05）；患者经2个周期化疗后β2-MG和CA125的水平较治疗前下降（P〈0.05）。结论血清β2-MG和CA125水平检测可作为NHL诊断、疾病恶性程度、分期、疗效评估的参考指标。
Objective To investigate the clinical significance of the serum β2-MG and CA125 in non-Hodgkin lymphoma （NHL）. Methods The level of serumβ2-MG and CA125 in 76 patients with NHL （NHL group） and 32 healthy subjects （control group） weredetected.The relationships between them and clinical characteristics and prognosis were explored. Results The levels of serumβ2-MG and CA125 in NHL group were obviously higher than those in the control group （P〈0.05）.The levels of serum β2-MG and CA125 in NHL group were not significantly correlated with age and gender （P〉0.05）.The levels of serumβ2-MG and CA125 in aggressive and high-aggressive NHL were obviously higher than those in indolent NHL （P〈0.05）.The levels of serumβ2-MG and CA125 in Ⅲ-Ⅳ stage were obviously higher than those inⅠ-Ⅱ stage （P〈0.05）.The levels of serumβ2-MG and CA125 were significantly decreased after two cycles of chemotherapy （P〈0.05）. Conclusion The levels of serum β2-MG and CA125 can be taken as reference index for diagnosis,invasiveness,classification,effectiveness of treatment in the patients with NHL.
出处
《中国当代医药》
2014年第23期51-53,共3页
China Modern Medicine
关键词
非霍奇金淋巴瘤
Β2-微球蛋白
CA125抗原
Non-Hodgkin lymphoma（NHL）
β2-microglobulin（β2-MG）
Carbohydrate antigen 125 （CA125）
